Showing results (211-220 of 219) with videos related to
Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
Journal for Immunotherapy of Cancer|January 11, 2024
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2026
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848Ross A Abrams, Kathryn A Winter, Karyn A Goodman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaMilind Javle, Maeve Lowery, Rachna T Shroff, et al.Biorxiv : the Preprint Server for Biology|January 23, 2026
Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable PathwaysMd Hafiz Uddin, Zaid Mahdi, Irfana Muqbil, et al.JCO Precision Oncology|March 6, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working GroupLakshmi Rajdev, Gentry G King, Christopher H Lieu, et al.Biorxiv : the Preprint Server for Biology|December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaHusain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.JAMA Surgery|December 4, 2024
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal AdenocarcinomaJordan M Cloyd, Angela Sarna, Matthew J Arango, et al.Pageof 22